E
Eupry
Unlocking home medication with pharma grade storage compliance as a service
About Eupry
Eupry specializes in providing temperature and humidity monitoring solutions for regulated industries such as pharmaceuticals, biotechnology, and healthcare logistics. The company addresses the critical need for compliance with standards like GxP and FDA 21 CFR Part 11, which are essential for ensuring the safety and efficacy of sensitive products.
The core of Eupry's offering is a system that combines hardware (Wi-Fi-based data loggers) and software to automate the tracking of environmental conditions in real-time. This allows clients to monitor temperature and humidity levels continuously from any device, receive alerts for deviations, and maintain a complete audit trail for regulatory purposes. The business model appears to be a combination of selling hardware and a recurring subscription for the software and service (SaaS), which includes monitoring, calibration, and mapping services under one platform.
Eupry serves a range of clients, from individual pharmacies to larger laboratory and pharmaceutical operations. By automating compliance tasks, the company helps its clients reduce the time and resources spent on manual monitoring, minimize the risk of product loss due to environmental excursions, and streamline the audit process. The service is designed to be stable and reliable, providing a centralized system for all temperature-related compliance documentation.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Copenhagen, Denmark
- Employees
- 111
- Open positions
- 5
- Dealroom signal
- 91.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Document Management, WiFi, Biotechnology, Sensors, Nordic Rising Star 2022, Hard Tech, DT and LS, science-based
- Technology
- IoT InternetOfThings
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2024 | $25M | $100M | Ugly Duckling Ventures · Export and Investment Fund of Denmark · Sagitta Family Office · Chr. Augustinus Fabrikker | ↗ |
| EARLY VC✓Equity / VC | Aug 2022 | $2.6M | $10M | Ugly Duckling Ventures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Eupry is 31K monthly website visits, down 27.9% over the last three months. Eupry's team grew 14.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Ugly Duckling Ventures
Chr. Augustinus Fabrikker
Export and Investment Fund of Denmark
Sagitta Family Office
Other known investors6 additional known investors
- AFAage & Yelva Nimbs Fond
- LNLars Neupart
- NKNiels Korsholm
Peter Sandberg
Steen Ulf Jensen- TFTranes Fond
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Eupry on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eupry’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







